Compare ONFO & GCTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONFO | GCTK |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.6M |
| IPO Year | N/A | 2011 |
| Metric | ONFO | GCTK |
|---|---|---|
| Price | $0.15 | $0.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.9M | 417.0K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.65 |
| Revenue | N/A | ★ $589,462.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.20 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.14 | $0.29 |
| 52 Week High | $2.48 | $14.14 |
| Indicator | ONFO | GCTK |
|---|---|---|
| Relative Strength Index (RSI) | 23.13 | 65.09 |
| Support Level | N/A | $0.43 |
| Resistance Level | $0.59 | $0.73 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 1.81 | 75.07 |
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place. The company operates in two business segments: Business to Business (B2B) and Business to Consumers (B2C). The majority of its revenue is generated from the Business-to-Business (B2B) segment, which includes the results of operations of Eastern Standard, RevenueZen, DDS Rank, SEO Butler, Contentellect, DealPipe, and Pace Generative.
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.